Cerus Corp (CERS)
1.745
+0.02
(+1.45%)
USD |
NASDAQ |
May 02, 16:00
1.74
0.00 (0.00%)
After-Hours: 17:06
Cerus Research and Development Expense (Quarterly): 14.29M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.29M |
| September 30, 2023 | 16.78M |
| June 30, 2023 | 19.18M |
| March 31, 2023 | 17.38M |
| December 31, 2022 | 18.61M |
| September 30, 2022 | 16.22M |
| June 30, 2022 | 15.22M |
| March 31, 2022 | 14.06M |
| December 31, 2021 | 15.57M |
| September 30, 2021 | 15.29M |
| June 30, 2021 | 17.08M |
| March 31, 2021 | 15.75M |
| December 31, 2020 | 17.06M |
| September 30, 2020 | 15.92M |
| June 30, 2020 | 15.62M |
| March 31, 2020 | 15.81M |
| December 31, 2019 | 16.44M |
| September 30, 2019 | 16.08M |
| June 30, 2019 | 14.42M |
| March 31, 2019 | 13.44M |
| December 31, 2018 | 12.42M |
| September 30, 2018 | 10.82M |
| June 30, 2018 | 9.881M |
| March 31, 2018 | 9.437M |
| December 31, 2017 | 7.783M |
| Date | Value |
|---|---|
| September 30, 2017 | 7.886M |
| June 30, 2017 | 8.891M |
| March 31, 2017 | 9.15M |
| December 31, 2016 | 8.815M |
| September 30, 2016 | 7.033M |
| June 30, 2016 | 8.557M |
| March 31, 2016 | 6.917M |
| December 31, 2015 | 7.16M |
| September 30, 2015 | 7.689M |
| June 30, 2015 | 5.213M |
| March 31, 2015 | 5.581M |
| December 31, 2014 | 5.186M |
| September 30, 2014 | 7.25M |
| June 30, 2014 | 4.722M |
| March 31, 2014 | 4.642M |
| December 31, 2013 | 4.618M |
| September 30, 2013 | 4.363M |
| June 30, 2013 | 3.506M |
| March 31, 2013 | 2.70M |
| December 31, 2012 | 2.164M |
| September 30, 2012 | 1.903M |
| June 30, 2012 | 1.712M |
| March 31, 2012 | 1.824M |
| December 31, 2011 | 1.562M |
| September 30, 2011 | 1.814M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
14.06M
Minimum
Mar 2022
19.18M
Maximum
Jun 2023
16.15M
Average
15.92M
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 6.08M |
| Retractable Technologies Inc | 0.1617M |
| Xtant Medical Holdings Inc | 0.492M |
| Asensus Surgical Inc | 8.614M |
| Catheter Precision Inc | -0.011M |